HomeInsightsPE

Glenmark Pharmaceuticals Ltd PE Ratio

Glenmark Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.7 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

5.0 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

PE

-

Last updated on: Nov 23, 2024

Key Highlights

  • The P/E Ratio of Glenmark Pharmaceuticals Ltd is 0 as of 23 Nov 09:23 AM .
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 19.7 on March 2019 to 0 on March 2024 . This represents a CAGR of -100.00% over 6 years.
  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1480 as of 22 Nov 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Glenmark Pharmaceuticals Ltd

No data available

Company Fundamentals for Glenmark Pharmaceuticals Ltd

No data available

Image

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

Share Price

₹ 1480.05

14.75 (1.01%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Glenmark Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Glenmark Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 20241480.05
21 Nov 20241465.3
19 Nov 20241492.35
18 Nov 20241483.5
14 Nov 20241531.7
13 Nov 20241538.5
12 Nov 20241577.25
11 Nov 20241634.7
08 Nov 20241665.5
07 Nov 20241657.7

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Glenmark Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Glenmark Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Glenmark Pharmaceuticals Ltd

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.
  • The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Ltd spurts 2.5%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoti...

Read more

2024-08-21 00:00:00

News

Glenmark Pharmaceuticals Ltd soars 4.33%, rises for third straight session

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting...

Read more

2024-08-19 00:00:00

News

Glenmark Pharma gains after American subsidiary launches Olopatadine generic

The solution is the generic version of 'Pataday Twice Daily Relief', which is distributed ...

Read more

2024-08-19 00:00:00

News

Glenmark launches Olopatadine Hydrochloride Ophthalmic Solution

Glenmark Therapeutics Inc., USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalm...

Read more

2024-08-19 00:00:00

News

Glenmark Pharma gains on reporting muti-fold jump in Q1 PAT

Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the qua...

Read more

2024-08-16 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Glenmark Pharmaceuticals Ltd

What is the current PE Ratio of Glenmark Pharmaceuticals Ltd?

The Current PE Ratio of Glenmark Pharmaceuticals Ltd is 0.0 as on 23 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 23 Nov 2024.

What was the PE Ratio of Glenmark Pharmaceuticals Ltd last year?

The PE Ratio of Glenmark Pharmaceuticals Ltd was 44.16 last year, now the PE ratio is 0.0, showing a year-on-year growth of -100.0%.

What does the PE Ratio of Glenmark Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Glenmark Pharmaceuticals Ltd is 0.0. This ratio indicates that investors are willing to pay 0.0 times the earnings per share for each share of Glenmark Pharmaceuticals Ltd.

What is the PE Ratio Growth of Glenmark Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Glenmark Pharmaceuticals Ltd grew by -100.0% whereas, the EPS ratio grew by 4.1.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*